BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at Citizens Jmp

BeOne Medicines (NASDAQ:ONC) had its price objective lifted by Citizens Jmp from $405.00 to $463.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp‘s target price would suggest a potential upside of 14.36% from the stock’s current price.

Several other research firms have also issued reports on ONC. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a research note on Thursday, October 1st. Wells Fargo & Company raised their price target on shares of BeOne Medicines from $400.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday. Nomura lifted their price target on shares of BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Truist Financial increased their price objective on shares of BeOne Medicines from $418.00 to $420.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $430.46.

BeOne Medicines Price Performance

ONC stock traded up $17.62 during midday trading on Friday, reaching $404.87. 351,349 shares of the stock were exchanged, compared to its average volume of 316,822. The stock has a market capitalization of $44.45 billion, a PE ratio of 71.06 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The company has a fifty day moving average price of $362.80 and a 200 day moving average price of $325.98. BeOne Medicines has a 52 week low of $253.95 and a 52 week high of $409.80.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $1.30. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.76 billion. As a group, analysts expect that BeOne Medicines will post 8.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other BeOne Medicines news, CEO John Oyler sold 54,892 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total transaction of $19,659,569.80. Following the transaction, the chief executive officer directly owned 240,743 shares in the company, valued at approximately $86,222,105.45. This trade represents a 18.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Titus B. Ball sold 132 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $355.86, for a total transaction of $46,973.52. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 376,373 shares of company stock worth $134,848,154 in the last three months. 6.19% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently made changes to their positions in ONC. Bank of America Corp DE boosted its stake in BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after acquiring an additional 26,441 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of BeOne Medicines by 5.5% in the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock worth $105,148,000 after acquiring an additional 19,327 shares during the period. Candriam S.C.A. boosted its stake in BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after purchasing an additional 62,470 shares during the period. First Trust Advisors LP increased its position in shares of BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after buying an additional 115,601 shares during the period. Finally, Jennison Associates LLC increased its position in shares of BeOne Medicines by 102.1% during the first quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock valued at $45,871,000 after buying an additional 78,027 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported third-quarter EPS of $3.64, topping the $2.34 consensus estimate, while revenue of $1.89 billion exceeded expectations of $1.76 billion. The company also raised its 2026 revenue guidance, adding to the positive outlook. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. The review could bring a decision on the potential label expansion sooner, creating an opportunity to broaden the treatment’s use if approved. FDA Priority Review for BRUKINSA Combination

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.